



EHA2026 Congress

June 11–14, 2026
Stockholm, Sweden



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

Thank you to the funders of the Lymphoma Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our current funders can be found at: [LymphomaHub.com](https://www.lymphomahub.com).

EHA2026: Top abstracts in lymphoma and CLL

June 11–14, 2026

Oral presentations: Thursday, June 11

Abstract	Title	Presenter	Time (CEST)
S226 View	Safety and efficacy of subcutaneous mosunetuzumab plus lenalidomide induction therapy followed by mosunetuzumab maintenance in previously untreated follicular lymphoma	Emmanuel Bachy	17:00–17:15
S227 View	Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ±rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Phase (Ph) 1/2 study long-term follow-up (f/u)	Daniel Morillo	17:15–17:30
S228 View	Surovatamig (AZD0486) plus rituximab in previously untreated follicular lymphoma (FL): Initial safety data from the phase 3 SOUNDTRACK-F1 trial	Chan Y. Cheah	17:30–17:45
S229 View	Clinically relevant subgroup analysis from the randomized phase 3 EPCORE FL-1 trial: Treatment (Tx) effect of epcoritamab with lenalidomide and rituximab (R ²) in R/R follicular lymphoma (FL)	Benoit Tessoulin	17:45–18:00
S245 View	VT-EBV-N as post-remission therapy significantly improves disease-free survival in EBV-positive extranodal NK/T-cell lymphoma: A randomized, double-blind phase 2 trial	Deok-Hwan Yang	16:45–17:00
S248 View	Brentuximab vedotin plus CHP plus etoposide (CHEPA) in newly diagnosed CD30- positive peripheral T-cell lymphomas with integrated ctDNA analysis: Primary results of the phase 2 CHEPA trial	Marek Trněný	17:30–17:45
S249 View	High-dose methotrexate does not reduce risk of CNS relapse in ultra high-risk large B-cell lymphoma: An international retrospective analysis of 1,923 patients	Matthew R. Wilson	17:45–18:00

Oral presentations: Friday, June 12, 2026

Abstract	Title	Presenter	Time (CEST)
S145 View	First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53	Chan Y. Cheah	17:15–17:30
S146 View	Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Final results of the randomized CLL14 study	Kirsten Fischer	17:30–17:45
S148 View	A phase 2 study of fixed-duration pirtobrutinib and obinutuzumab in previously untreated CLL	Inhye E. Ahn	18:00–18:15
S149 View	Genetic biomarkers predicting sustained efficacy of venetoclax-based therapies or CIT in chronic lymphocytic leukemia: Final 5-year analysis of the GAIA/CLL13 trial	Eugen Tausch	18:15–18:30

Oral presentations: Friday, June 12, 2026 (continued)

Abstract	Title	Presenter	Time (CEST)
S221 View	Final analysis of the GHSG HD21 older cohort: Efficacy, survival and late toxicity of PET-guided BrECADD in older patients with advanced-stage classic Hodgkin lymphoma	Justin Ferdinandus	17:30–17:45
S222 View	Avelumab in the front-line treatment of advanced classical Hodgkin lymphoma (AVENUE)- Final 3-year results of phase II study	Aisling Barrett	17:45–18:00
S235 View	Results from EPCORE DLBCL-1: Randomized phase 3 study of epcoritamab (EPCOR) vs investigator's choice chemoimmunotherapy (CIT) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)	Christopher P. Fox	17:15–17:30
S236 View	Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell non-Hodgkin lymphoma (ANTLER phase 1 clinical trial)	Stephen Schuster	17:30–17:45
S238 View	Safety data and initial pooled efficacy data from the Nordic Lymphoma Group phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma - R-Pola-mini-CHP vs. R-mini-CHOP	Mats Jerkeman	18:00–18:15
S239 View	Golcadomide (GOLCA), a potential, first-in-class oral CELMoD + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (A-BCL): Safety and 12-month efficacy from a phase 1b study	Maria Bouzani	18:15–18:30

Oral presentations: Saturday, June 13, 2026

Abstract	Title	Presenter	Time (CEST)
S101 View	Tafasitamab plus lenalidomide and R-CHOP for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase 3 frontMIND study	Georg Lenz	12:30–12:45
S241 View	Comprehensive analysis of bridging to CAR T-cell therapy in large B-cell lymphoma with conventional treatment or CD3XCD20 bispecific antibodies	Ruth Fluemann	17:30–17:45

Oral presentations: Sunday, June 14, 2026

Abstract	Title	Presenter	Time (CEST)
LB5001 View	Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: A phase 3, randomized trial (BRUIN CLL-322)	Matthew Davids	09:15–09:30
LB5006 View	First-in-human trial of LB2501, an <i>in vivo</i> CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-cell NHL	Lei Fan	10:30–10:45
S150 View	Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy	Talha Munir	11:00–11:15
S152 View	BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A phase 1 CaDAnCe-101 study update	Stephan Stilgenbauer	11:30–11:45
S153 View	Fixed duration venetoclax plus epcoritamab shows favorable tolerability and high response rates with early molecular responses in R/R CLL/SLL: Interim analysis of the randomized HOVON 165/AETHER trial	Arnon Philip Kater	11:45–12:00
S232 View	Fixed-duration glofitamab monotherapy in relapsed or refractory mantle cell lymphoma with or without prior Bruton's tyrosine kinase inhibitor exposure: Updated outcomes with 3.5 years of follow-up	Yasmin Karimi	11:30–11:45
S256 View	Circulating tumor DNA reveals lymphoma-associated mutations long before clinical diagnosis	Nick Veltmaat	11:15–11:30

Posters

Abstract	Title	Presenter	Date and time (CEST)
PF606 View	Safety and efficacy of dose-modified approaches of fixed-duration (FD) ibrutinib+venetoclax (I+V) in patients with previously untreated CLL: Primary analysis of the prospective phase 2 TAILOR study	Paolo Ghia	Friday, June 12, 18:45–19:45
PF614 View	Safety of fixed-duration (FD) acalabrutinib-venetoclax combinations in patients (pts) with chronic lymphocytic leukemia (CLL) stratified by age: Post hoc analysis of the phase 3 AMPLIFY trial	John F. Seymour	Friday, June 12, 18:45–19:45
PF915 View	A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA)	Pier Luigi Zinzani	Friday, June 12, 18:45–19:45
PF948 View	Phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment	Stefano Luminari	Friday, June 12, 18:45–19:45

Posters (continued)

Abstract	Title	Presenter	Date and time (CEST)
PF963 View	Five-year follow-up of patients with relapsed/refractory large B-cell lymphoma who achieved a complete response with glofitamab monotherapy	Krish Patel	Friday, June 12, 18:45–19:45
PF968 View	Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the phase 3 SUNMO study including in patient subgroups	L. Elizabeth Budde	Friday, June 12, 18:45–19:45
PF975 View	Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy in relapsed/refractory large B-cell lymphoma: Crossover analysis (third-line) from the randomized, pivotal DALY 2-EU trial	Peter Vandenberghe	Friday, June 12, 18:45–19:45
PF977 View	Sustained remissions beyond 4 years with epcoritamab monotherapy: Long-term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma	Catherine Thieblemont	Friday, June 12, 18:45–19:45
PS1689 View	Initial results of multicenter phase 2 BOVen-ΔMRD400 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) with treatment duration guided by MRD kinetics (ΔMRD400) in treatment-naïve (TN) CLL	Jacob Soumerai	Saturday, June 13, 18:45–19:45
PS1701 View	Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314	Jennifer Woyach	Saturday, June 13, 18:45–19:45



#EHA2026

Follow us on X to keep up to date
with the latest from the congress

@LymphomaHub



Brought to you by

